Julia Tietz, Tea Gunde, Stefan Warmuth, Christopher Weinert, Matthias Brock, Alexandre Simonin, Christian Hess, Maria Johansson, Fabio Spiga, Simone Muntwiler, Belinda Wickihalder, Dana Mahler, Dania Diem, Julia Zeberer, Robin Heiz, Naomi Flückiger, Noriko Shiraishi, Yoshihide Miyake, Nobuaki Takahashi, Markus Fehrholz, Marta Bertolini, Peter Lichtlen, David Urech, Daniel Snell
Inhibition of IL-4/IL-13 signaling has dramatically improved the treatment of atopic dermatitis (AD). However, in many patients, clinical responses are slow to develop and remain modest. Indeed, some symptoms of AD are dependent on IL-31, which is only partially reduced by IL-4/IL-13 inhibition. Thus, there is an unmet need for AD treatments that concomitantly block IL-4/IL-13 and IL-31 pathways. We engineered NM26-2198, a bispecific tetravalent antibody designed to accomplish this task. In reporter cell lines, NM26-2198 concomitantly inhibited IL-4/IL-13 and IL-31 signaling with a potency comparable with that of the combination of an anti-IL-4Rα antibody (dupilumab) and an anti-IL-31 antibody (BMS-981164)...
March 2024: JID innovations